PMID- 37604426
OWN - NLM
STAT- MEDLINE
DCOM- 20231121
LR  - 20231121
IS  - 2213-2201 (Electronic)
VI  - 11
IP  - 11
DP  - 2023 Nov
TI  - Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, 
      Differ Demographically, Clinically, and in Response to Treatment-Results From 
      CURE.
PG  - 3515-3525.e4
LID - S2213-2198(23)00924-8 [pii]
LID - 10.1016/j.jaip.2023.08.020 [doi]
AB  - BACKGROUND: Patients with chronic spontaneous urticaria (CSU) have spontaneous 
      wheals (W), angioedema (AE), or both, for longer than 6 weeks. Clinical 
      differences between patients with standalone W, standalone AE, and W and AE 
      (W+AE) remain incompletely understood. OBJECTIVE: To compare W, AE, and W+AE CSU 
      patients regarding demographics, disease characteristics, comorbidities, disease 
      burden, and treatment response. METHODS: Baseline data from 3,698 CSU patients in 
      the ongoing, prospective, international, multicenter, observational Chronic 
      Urticaria REgistry (CURE) were analyzed (data cut: September 2022). RESULTS: 
      Across all CSU patients, 59%, 36%, and 5% had W+AE, W, and AE, respectively. The 
      W+AE patients, compared with W and AE patients, showed the lowest male-to-female 
      ratio (0.33), higher rates of concomitant psychiatric disease (17% vs 11% vs 6%, 
      respectively), autoimmune disease (13% vs 7% vs 9%, respectively), and 
      nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity (9% vs 5% vs 2%, 
      respectively) and the highest disease impact. The W patients, compared with W+AE 
      and AE patients, showed the lowest rates of concomitant hypertension (15% vs 21% 
      vs 40%, respectively) and obesity (11% vs 16% vs 17%, respectively), the highest 
      rate of concomitant inducible urticaria (24% vs 22% vs 6%, respectively), and 
      shorter W duration. The AE patients, compared with W+AE and W patients, were 
      older at disease onset, showed longer AE duration, and the best response to 
      increased doses of H(1)-antihistamines (58% vs 24% vs 31%, respectively) and 
      omalizumab (92% vs 67% vs 60%, respectively). CONCLUSIONS: Our findings provide a 
      better understanding of CSU phenotypes and may guide patient care and research 
      efforts that aim to link them to pathogenic drivers.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Buttgereit, Thomas
AU  - Buttgereit T
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
FAU - Vera, Carolina
AU  - Vera C
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
FAU - Aulenbacher, Felix
AU  - Aulenbacher F
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
FAU - Church, Martin K
AU  - Church MK
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
FAU - Hawro, Tomasz
AU  - Hawro T
AD  - Institute and Comprehensive Center for Inflammation Medicine, Department of 
      Dermatology, Allergology and Venerology, University Medical Center 
      Schleswig-Holstein, Lubeck, Germany.
FAU - Asero, Riccardo
AU  - Asero R
AD  - Department of Allergology, Clinica San Carlo, Paderno Dugnano, Milan, Italy.
FAU - Bauer, Andrea
AU  - Bauer A
AD  - Department of Dermatology, University Hospital, Carl Gustav Carus, Technical 
      University Dresden, Dresden, Germany.
FAU - Bizjak, Mojca
AU  - Bizjak M
AD  - Division of Allergy, University Clinic of Respiratory and Allergic Diseases 
      Golnik, Golnik, Slovenia.
FAU - Bouillet, Laurence
AU  - Bouillet L
AD  - CREAK (Centre national de reference des angioedemes), Internal Medicine, CHU 
      Grenobles Alpes, Grenoble, France.
FAU - Dissemond, Joachim
AU  - Dissemond J
AD  - Department of Dermatology, Venerology and Allergology, University of Essen, 
      Essen, Germany.
FAU - Fomina, Daria
AU  - Fomina D
AD  - Center of Allergy and Immunology, Clinical State Hospital 52, Moscow Healthcare 
      Ministry, Moscow, Russian Federation; I. M. Sechenov First Moscow State Medical 
      University (Sechenov University), Department of Clinical Immunology and 
      Allergology, Moscow, Russian Federation.
FAU - Gimenez-Arnau, Ana M
AU  - Gimenez-Arnau AM
AD  - Department of Dermatology, Institut Mar de Investigacions Mediques, Universitat 
      Pompeu Fabra, Barcelona, Spain.
FAU - Grattan, Clive
AU  - Grattan C
AD  - Guy's Hospital, St. John's Institute of Dermatology, London, UK.
FAU - Gregoriou, Stamatios
AU  - Gregoriou S
AD  - National and Kapodistrian University of Athens, 1st Department of 
      Dermatology-Venereology, Andreas Sygros Hospital. Athens, Greece.
FAU - Kulthanan, Kanokvalai
AU  - Kulthanan K
AD  - Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Kasperska-Zajac, Alicja
AU  - Kasperska-Zajac A
AD  - European Center for Diagnosis and Treatment of Urticaria/Angioedema (GA(2)LEN 
      UCARE Network), Medical University of Silesia in Katowice, Katowice, Poland.
FAU - Kocaturk, Emek
AU  - Kocaturk E
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany; Department of 
      Dermatology, Koc University School of Medicine, Istanbul, Turkey.
FAU - Makris, Michael
AU  - Makris M
AD  - Allergy Unit "D. Kalogeromitros", 2nd Department, Dermatology and Venereology, 
      National and Kapodistrian University of Athens, "Attikon" University Hospital, 
      Athens, Greece.
FAU - Kolkhir, Pavel
AU  - Kolkhir P
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
FAU - Weller, Karsten
AU  - Weller K
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
FAU - Magerl, Markus
AU  - Magerl M
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
FAU - Maurer, Marcus
AU  - Maurer M
AD  - Institute of Allergology, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany; 
      Institute of Allergology, Fraunhofer Institute for Translational Medicine and 
      Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany. Electronic 
      address: marcus.maurer@charite.de.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20230819
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 0 (Anti-Allergic Agents)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - *Angioedema/drug therapy/epidemiology/complications
MH  - *Anti-Allergic Agents/therapeutic use
MH  - Chronic Disease
MH  - *Chronic Urticaria/drug therapy/epidemiology
MH  - Omalizumab/therapeutic use
MH  - Prospective Studies
MH  - *Urticaria/drug therapy/epidemiology
OTO - NOTNLM
OT  - Angioedema
OT  - CSU
OT  - CURE registry
OT  - Chronic spontaneous urticaria
OT  - Recurrent
OT  - Without wheals
EDAT- 2023/08/22 00:41
MHDA- 2023/11/13 06:42
CRDT- 2023/08/21 19:33
PHST- 2023/04/06 00:00 [received]
PHST- 2023/07/19 00:00 [revised]
PHST- 2023/08/05 00:00 [accepted]
PHST- 2023/11/13 06:42 [medline]
PHST- 2023/08/22 00:41 [pubmed]
PHST- 2023/08/21 19:33 [entrez]
AID - S2213-2198(23)00924-8 [pii]
AID - 10.1016/j.jaip.2023.08.020 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2023 Nov;11(11):3515-3525.e4. doi: 
      10.1016/j.jaip.2023.08.020. Epub 2023 Aug 19.